Codiak BioSciences — Corporate Update (June 2022)
26 slides from Codiak BioSciences's corporate update, Jun 30, 2022
Slide 1: exoSTING and exoIL-12 Clinical Update and Future Directions
June 30, 2022 exoSTINGTM and exoIL-12TM CLINICAL UPDATE and FUTURE DIRECTIONS Exhibit 99.2
Slide 2: Forward-Looking Statements and Disclaimers
Forward-Looking Statements and Disclaimers These slides and the accompanying presentation contain forward-looking statements and information within the meaning of the Private Securities Litigation Reform Act of 1995. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “antic
Slide 3: Achieved Intended Study Outcomes for this Data Release
Local retention and lack of systemic exposure of IL-12 Improved safety vs rIL-12 Confirmation of anti-tumor activity Deep and durable effects on injected and abscopal lesions RP2D in optimal study population GO to Phase 2 study 100-fold improved potency vs free STING agonist (SA) Lack of systemic SA
Slide 4: exoIL-12: Clinical Data Update
exoIL-12TM: Clinical Data Update
Slide 5: exoIL-12 Best-in-Class IL-12 Strategy
Despite clinical activity in multiple tumor types, IL-12 historically has had an Intolerable AE profile & dose limiting toxicity Narrow to nonexistent therapeutic window Several attempts to localize delivery via AAV, plasmid, mRNA Immuno-cytokine masking and local activation Surface display leveragi
Slide 6: exoIL-12 Two-part Design in Healthy Volunteers and Early Stage CTCL Patients
exoIL-12TM | Two-part Design in Healthy Volunteers and Patients with Early Stage CTCL PART A – HEALTHY VOLUNTEERS – SAD Screening DLT Safety PK Biomarkers PD Dosing Labs Biopsy Dosing PART B – CTCL STAGE IA-IIB – MAD Screening DLT Safety PK Biomarkers PD Dosing Labs Biopsy Dosing Clinical Activity C
Slide 7: exoIL-12: No systemic release of IL-12, enabling safety profile
exoIL-12TM: No systemic release of IL-12, enabling safety profile N=2 Dose: 6 mcg N=14 Weeks Plasma IL-12 Level Healthy Volunteers CTCL Patients Limit of quantification: 8 pg/mL All data points below limit of quantification (LOQ) exoIL-12 Dose
Slide 8: Minimal Induction of Systemic IFN following Single and Repeat Dosing
Minimal Induction of Systemic IFN following Single and Repeat Dosing in Healthy Volunteers and CTCL Patients Healthy Volunteers (SAD) CTCL Patients C1D1 C2D1 C2D15 C1D15 N=2 Dose: 6 mcg N=14 exoIL-12 Dose
Slide 9: exoIL-12: Demonstrates Potential Best-in-Class Safety Profile
exoIL-12TM : Demonstrates Potential Best-in-Class Safety Profile Current Safety Database 2 CTCL patients, each have received ~20 injections (6µg) to multiple lesions Duration of therapy >6 months 14 healthy volunteers administered single doses between 0.3-12µg Adverse Event Data No treatment-related
Slide 10: exoIL-12: Deep and Durable Responses in Injected and Uninjected Lesions
exoIL-12TM: Deep and Durable Responses in Injected and Uninjected Lesions Pt 102-001 (stage IIB) Pt 102-002 (Stage IA) Interim data Data cut-off 10 June 2022 exoIL-12 injection Week Week Right Thigh Left Thigh Stomach Left P Thigh R Arm Right Buttock Left Buttock Right Thigh
Slide 11: exoIL-12: Observed Lesion Resolution in Pt 102-001
exoIL-12: Observed Lesion Resolution in Pt 102-001 Pre Dose C4D1 Target Lesion 1 Target Lesion 1 Target Lesion 2 Target Lesion 2 Patient 102-001
Slide 12: exoIL-12: Observed Reduction in Disease Burden
exoIL-12TM: Observed Reduction in Disease Burden mSWAT= (%BSA Patch) + (%BSA Plaque x 2) + (%BSA Tumor x 4) Pt 001: >36 weeks on study; Partial Response, all lesions resolved. Remains on study for observation only. Pt 002: >20 weeks on study: Remains on study and continues to receive injections. Dat
Slide 13: exoIL-12: Preliminary Safety and Clinical Activity in CTCL Patients
exoIL-12TM: Preliminary Safety and Clinical Activity in CTCL Patients PROPRIETARY INFORMATION OF CODIAK BIOSCIENCES | Tumor retention of IL-12, no systemic exposure No systemic inflammatory cytokine related AEs Favorable safety and tolerability profile following multiple administrations of exoIL-12T
Slide 14: Prioritized Clinical Development Strategy
Prioritized Clinical Development Strategy Expand POC into other indications Combination with SOC (e.g. Merkel, melanoma, cSCC, Kaposi’s) Strengthen POC in CTCL Monotherapy in Stage II-III Combination in Stage III-IV Expand to neoadjuvant indications Combination with SOC in TNBC 6 µg will be utilized
Slide 15: exoSTING: Clinical Data Update
exoSTINGTM: Clinical Data Update
Slide 16: exoSTING | Novel, Differentiated STING Agonist
exoSTING™ |Novel, Differentiated STING Agonist Challenges of Free STING Agonists (FSAs) STING agonist targeted to tumor APC 100-fold potency increase, drug retention Lack of systemic STING agonist exposure Innate and adaptive immune activation T-Cell expansion/preservation Local and distal tumor res
Slide 17: Phase 1 Dose Escalation Study of Intratumoral exoSTING in R/R Solid Tumors
Phase 1 Dose Escalation Study of Intratumoral exoSTINGTM in Unselected Patients with R/R Solid Tumors Screening DLT CDK-002 Biomarkers PK/PD Dosing Labs Biopsy CT Scan Dosing Clinical Activity Safety Cycle 3+ Cycle 1 Cycle 2 DOSE ESCALATION, “3+3” DESIGN HNSCC, oral cavity Sarcoma, chondroid cSCC HC
Slide 18: exoSTING | No Systemic Exposure at Evaluated Doses
exoSTING™|No Systemic Exposure at Evaluated Doses Free STING Agonist (FSA) Meric-Bernstam et al., Clinc Cancer Res 2021 ADU-S100 Doses: 50, 100, 200, 400, 800. 1600, 3200 and 6400 mcg N=47 Codiak has not conducted a clinical comparison (n=4) (n=3) (n=6) (n=5) (n=3) exoSTING™ *all patients who receiv
Slide 19: exoSTING | Best-in-Class Safety Profile
0.3 ug (n=4) 1 ug (n=3) 3 ug (n=6) 6 ug (n=7) 12 ug (n=3) Overall (n=23) Subjects with TEAEs 4 (100) 2 ( 66.7) 6 (100) 5 (71.4) 3 (100) 20 (87.0) Subjects with treatment-related AEs 3 ( 75.0) 1 ( 33.3) 4 (66.7) 4 (57.1) 2 (66.7) 14 (60.9) Subjects with treatment-related AEs of Grade 3 or higher* 0 0
Slide 20: exoSTING | Dose Dependent STING Pathway Activation Without High Dose Inhibition
exoSTING™| Dose Dependent STING Pathway Activation Without High Dose Inhibition MK-1454 Free STING Agonist (FSA) Dose expansion at 540 mcg MK-1454 Abstract, ESMO 2019 IP-10/ CXCL10 Codiak has not conducted a clinical comparison. exoSTING CXCL10 mRNA N=19* *all patients who received ≥ 1 dose STING pa
Slide 21: exoSTING | Induces Increases in CD8 Effector T-cells and PD-L1 in the Tumor
exoSTING™ | Induces Consistent Increases in CD-8 Effector T-cells and PD-L1 in the Tumor Micro-environment Significant (>2 fold) T-cell infiltration and PD-L1 increase observed 6 of 7 subjects demonstrated increase in PD-L1 4 of 7 subjects demonstrated increased CD8 T-cell infiltration Consistent in
Slide 22: exoSTING | Demonstrates Tumor Regression in Heavily Pre-treated Patients
exoSTING™| Demonstrates Tumor Regression in Heavily Pre-treated Patients All target lesions (RECIST V1.1) Interim data Data cut-off June 10 2022
Slide 23: exoSTING: Best-In-Class STING Agonist Profile
exoSTINGTM: Best-In-Class STING Agonist Profile PROPRIETARY INFORMATION OF CODIAK BIOSCIENCES | Tumor retention of STING agonist, no systemic exposure Favorable safety and tolerability profile at doses tested Innate and adaptive immune activation PD dose response without T cell inhibition/ablation A
Slide 24: Rationale for Bladder Cancer
Rationale for Bladder Cancer Limited tumor burden in early-stage disease IT administration exposes entirety of tumor burden to exoSTING IT administration fits with standard urologic practice patterns Activation of STING pathway could lead to increased sensitivity to CPI therapies pCR rates in neoadj
Slide 25: Clinical Validation of the engEX Platform; GO Decision Achieved with Both Programs
Tumor retention of exo-therapies, no systemic exposure seen Favorable safety and tolerability profile at doses tested Antitumor activity in both injected and uninjected/distal lesions Clear differentiation and potential best-in-class therapies Phase 1 study objectives achieved Clinical development a
Slide 26: coBiak ‘ lis : ‘ RMATION OF CODIAK BIOSCIENCES |
coBiak ‘ lis : ‘ RMATION OF CODIAK BIOSCIENCES | —_— ———